Dicot

Executive Summary

Dicot Pharma, a Swedish biotech founded in 2017, is developing LIB-01, a novel small molecule for erectile dysfunction (ED) and premature ejaculation (PE). The company aims to address limitations of current treatments by offering longer duration, fewer side effects, and efficacy across a broader patient population. Having advanced to Phase 2 clinical trials, Dicot is positioned to generate pivotal efficacy and safety data. The ED market is large and growing, with high unmet need for non-PDE5 inhibitor alternatives. While competition exists, LIB-01's differentiated mechanism could capture significant share if successful. However, the company is private and early-stage, facing typical clinical and regulatory risks. With a strong scientific foundation and clear value proposition, Dicot represents a speculative but potentially high-reward opportunity in sexual health therapeutics.

Upcoming Catalysts (preview)

• H2 2026Phase 2 top-line data for LIB-01 in ED40% success
• Q4 2026Initiation of Phase 2 trial for premature ejaculation50% success
• 2027Partnership or licensing deal for LIB-0130% success